BR0314097A - Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano - Google Patents

Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano

Info

Publication number
BR0314097A
BR0314097A BR0314097-0A BR0314097A BR0314097A BR 0314097 A BR0314097 A BR 0314097A BR 0314097 A BR0314097 A BR 0314097A BR 0314097 A BR0314097 A BR 0314097A
Authority
BR
Brazil
Prior art keywords
chemotherapeutic agents
agents
taxane
anthracycline
chemotherapic
Prior art date
Application number
BR0314097-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Lorne J Brandes
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Publication of BR0314097A publication Critical patent/BR0314097A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0314097-0A 2002-09-04 2003-09-03 Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano BR0314097A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40767902P 2002-09-04 2002-09-04
PCT/CA2003/001340 WO2004022040A2 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

Publications (1)

Publication Number Publication Date
BR0314097A true BR0314097A (pt) 2005-07-19

Family

ID=31978506

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314097-0A BR0314097A (pt) 2002-09-04 2003-09-03 Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano

Country Status (11)

Country Link
US (1) US20060089317A1 (https=)
EP (1) EP1536779A2 (https=)
JP (1) JP2006516533A (https=)
KR (1) KR20050086415A (https=)
CN (1) CN1694691A (https=)
AU (1) AU2003266047A1 (https=)
BR (1) BR0314097A (https=)
CA (1) CA2497180A1 (https=)
MX (1) MXPA05002465A (https=)
RU (1) RU2005109421A (https=)
WO (1) WO2004022040A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063574T3 (es) * 1990-12-17 1995-01-01 Univ Manitoba Metodo de tratamiento mejorado para el cancer.
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
PL369792A1 (en) * 2001-11-01 2005-05-02 Ym Biosciences, Inc. Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
US20050119263A1 (en) * 2001-11-09 2005-06-02 Vincent Mark D. Treatment of breast cancer

Also Published As

Publication number Publication date
EP1536779A2 (en) 2005-06-08
KR20050086415A (ko) 2005-08-30
JP2006516533A (ja) 2006-07-06
AU2003266047A8 (en) 2004-03-29
WO2004022040A2 (en) 2004-03-18
CN1694691A (zh) 2005-11-09
AU2003266047A1 (en) 2004-03-29
CA2497180A1 (en) 2004-03-18
MXPA05002465A (es) 2005-12-14
RU2005109421A (ru) 2005-10-20
WO2004022040A3 (en) 2004-04-29
US20060089317A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
ECSP045433A (es) "uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario"
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
ATE329903T1 (de) Hochgradig lipophile camptothecin-derivate
AR029763A1 (es) Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
HN1998000155A (es) Medicamentos
DE602004027888D1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihr
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
ES2191187T3 (es) Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
UY28736A1 (es) Derivados de quinazolina
AR009741A1 (es) Nuevos derivados de la benzamidina, procedimiento para prepararlos, preparados farmaceuticos que los contienen y su empleo como medicamentos.
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
AR032432A1 (es) Combinaciones oncoliticas para el tratamiento de cancer
BR0010709B1 (pt) uso de lh para a produção de um medicamento para induzir a paucifoliculogênese ou unifoliculogênese em mulheres anovulatórias.
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
BR0314097A (pt) Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
AR041595A1 (es) Tratamiento terapeutico
AR029637A1 (es) Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
PE20020466A1 (es) Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.